On September 25, 2015, the Texas Board of Pharmacy issued proposed rules that will allow pharmacists to substitute interchangeable biological products for brand name drugs.
The U.S. Food and Drug Administration recently issued final guidance regarding the size, shape and other physical characteristics of generic-manufactured tablet and capsule dosage forms.
The IP Beacon is a Haynes and Boone Newsletter highlighting current issues in Intellectual Property Law.
The FDA recently issued final guidance regarding the size, shape, and other physical characteristics of generic-manufactured tablet and capsule dosage forms. The guidance noted that differences in phy...
The Washington, D.C. office of Haynes and Boone, LLP proudly announces the expansion of its Hatch-Waxman/ANDA Practice Group with the addition of Whitney Remily and
In recent remarks to a compliance conference for the pharmaceutical industry, the SEC’s Director of Enforcement, Andrew Ceresney, addressed FCPA issues that commonly arise in the industry.
Report by Jeff Becker, the Team Leader for INTA’s Government Officials Education and Training Committee.
The U.S. Supreme Court appeared divided Wednesday over whether the Federal Circuit should give more deference to claim construction decisions by lower courts, with some justices saying trial judges...
HOUSTON – Haynes and Boone, LLP Houston has welcomed U.S. patent lawyer John Demarco as a partner in the firm’s Intellectual Property Transactional Section.